Table 2.
Clinical features of the 13 early-stage pulmonary lymphoepithelioma-like carcinoma patients
| Patient ID | Age | Gender | Smoking status, smoking pack years | Disease stage | Treatment regimen received | Best response | Immunotherapy, best response | Number of CNVs detected | TMB (mutations/Mb) | PD-L1 TPS (%) | Degree of lymphoid cell infiltration | Date of diagnosis | OS as of last follow-up date (months) | Survival status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P05 | 59 | Male | Smoker, 20 | IB | RT | SD | No | 0 | 3.2 | 0 | 10% | 2017/2/8 | 14.0 | Alive |
| P17 | 38 | Male | Smoker, 40 (10 years water pipe) | IIA | S + adj CT | SD | No | 0 | 1.6 | 20 | 40% | 2017/1/4 | 19.9 | Alive |
| P22 | 55 | Male | Smoker, 40 | IIA | S + adj CT | – | No | 0 | 0.8 | 5 | 40% | 2018/12/1 | 0.1 | Alive |
| P04 | 39 | Male | Smoker, 10 | IIB | S + adj CT | SD | No | 0 | 0a | 0 | 50% | 2016/12/7 | 14.9 | Alive |
| P08 | 56 | Female | No | IIB | Neo CT + S + adj CT | – | Nivolumab, SD | 7 | 27.8 | 30 | 20% | 2017/10/2 | 14.2 | Alive |
| P24 | 57 | Female | No | IIB | S | – | No | 0 | 2.4 | 60 | 10% | 2018/12/13 | 0.2 | Alive |
| P01 | 43 | Male | Smoker, 1 | IIIA | Neo CT + S + adj CT + RT | SD | No | 0 | 1.6 | 0 | 40% | 2015/7/1 | 41.4 | Alive |
| P02 | 55 | Female | No | IIIA | Neo CT + S + adj CT | SD | No | 0 | 1.6 | 30 | 40% | 2016/10/31 | 6.3 | Alive |
| P23 | 48 | Male | Smoker, 15 | IIIA | S + adj CT | SD | No | 0 | 1.6 | 2 | 40% | 2015/7/26 | 39.9 | Alive |
| P14 | 58 | Female | No | IIIA | S + adj CT | SD | No | 2 | 3.2 | 2 | 40% | 2015/8/7 | 37.2 | Alive |
| P20 | 64 | Male | Smoker, 10 | IIIA | CT | PR | No | 7 | 4 | 0 | 30% | 2018/4/17 | 7.5 | Alive |
| P27 | 64 | Female | No | IIIA | CT | – | No | 0 | 3.2 | 20 | 50% | 2018/11/23 | 0.9 | Alive |
| P15 | 47 | Female | No | IIIA | CT | PR | No | 2 | 0.8 | 50 | 5% | 2016/9/15 | 27.4 | Alive |
– Data not available
Adj CT adjuvant chemotherapy, CNV copy number variation, CT chemotherapy, Neo CT neoadjuvant chemotherapy, OS overall survival, PR partial response, RF relapse-free, RT radiotherapy, S surgery, SD stable disease, TMB tumor mutation burden, TPS tumor positive score
aPatient P04 was wild-type in all the genes in the panel used